BiotechTube
Home/Enanta Pharmaceuticals/Matthew P. Kowalsky, J.D.
MP

Matthew P. Kowalsky, J.D.

Chief Legal Officer

Enanta Pharmaceuticals

Therapeutic Areas

VirologyImmunology

Enanta Pharmaceuticals Pipeline

DrugIndicationPhase
Zelicapavir (EDP-938)Respiratory Syncytial Virus (RSV) InfectionPhase 2
EDP-323Respiratory Syncytial Virus (RSV) InfectionPhase 2a
EDP-235COVID-19 (SARS-CoV-2 Infection)Phase 2
EDP-978Type 2 Immune Diseases (e.g., Chronic Spontaneous Urticaria)Pre-clinical
STAT6 Inhibitor ProgramType 2 Inflammatory DiseasesPre-clinical
MRGPRX2 Inhibitor ProgramType 2 Inflammatory DiseasesPre-clinical

Leadership Team at Enanta Pharmaceuticals

JR
Jay R. Luly, Ph.D.
President, Chief Executive Officer and Director
TL
Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
View full Enanta Pharmaceuticals profile